Table 2.
Median OS according to patients’ characteristics at baseline. Italy, 2013–2021.
| Characteristic | Median OS (95% CI) | p-Value a |
|---|---|---|
| Sex | ||
| Females | 9.9 (6.6–12.0) | |
| Males | 8.0 (6.8–10.3) | 0.75 |
| Age at diagnosis (years) | ||
| <70 | 15.5 (8.6–20.8) | |
| 70–74 | 7.5 (4.9–11.0) | |
| 75–79 | 8.6 (6.6–10.8) | |
| ≥80 | 9.5 (3.5–12.5) | 0.16 |
| ECOG PS | ||
| 0 | 11.0 (6.6–18.4) | |
| 1 | 7.7 (5.4–9.5) | |
| ≥2 | 10.3 (6.9–12.1) | 0.19 |
| Type of AML | ||
| De novo | 8.0 (6.2-11.5) | |
| Secondary | 8.7 (6.9-11.0) | 0.045 |
| Comorbidities | ||
| No | 11.0 (6.6–19.7) | |
| 1 | 9.5 (6.2–11.8) | |
| 2 | 8.0 (5.4–12.0) | |
| ≥3 | 7.4 (4.7–10.8) | 0.65 |
| Molecular biology profile | ||
| Favorable | 9.0 (3.5–94.0) | |
| Intermediate | 9.6 (7.5–12.1) | |
| Adverse | 5.5 (0.7–19.0) | 0.44 |
| Not available | 7.8 (4.9–9.9) | |
| Karyotype profile b | ||
| Favorable/Intermediate | 9.6 (7.4–12.1) | |
| Adverse | 7.7 (3.6–10.3) | 0.12 |
| Not available | 8.6 (3.2–14.0) | |
| Blasts (%) | ||
| ≤30 | 10.3 (7.4–12.1) | |
| >30 | 8.0 (6.6–9.9) | 0.34 |
| Haemoglobin (g/dL) c | ||
| <7.5 | 10.3 (7.7–15.2) | |
| 7.5–<8.2 | 6.8 (3.6–9.9) | |
| 8.2–<9 | 7.4 (3.5–12.1) | |
| ≥9 | 9.8 (6.9–15.5) | 0.09 |
| WBC count c | ||
| <1810 | 8.2 (6.9–12.5) | |
| 1810–<4000 | 8.6 (5.6–11.8) | |
| 4000–<19,210 | 9.0 (5.3–14.7) | |
| ≥19,210 | 7.7 (4.8–11.5) | 0.87 |
| Platelet count c | ||
| <21,000 | 7.7 (4.3–13.1) | |
| 21,000–<45,000 | 8.0 (4.8–12.0) | |
| 45,000–<89,000 | 7.5 (4.9–11.0) | |
| ≥89,000 | 10.0 (8.0–15.6) | 0.87 |
| Total patients | 8.7 (7.4–10.3) |
AML: acute myeloid leukemia; CI: confidence interval; OS: overall survival; WBC: white blood cell. Statistically significant results are reported in bold. a Log-rank tests. “Not available” category, not included in the calculation. b Only 5 (2.5%) patients had a favourable karyotype profile thus favorable and intermediate profiles were grouped together. c Distribution according to approximate quartiles.